EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
   3.2.1.83 | Graft vs Host Disease |
32654464 |
[Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation]. |
causal interaction
diagnostic usage
ongoing research
unassigned |
1
3
2
0 |
| 3.2.1.83 | Leukemia |
26212611 |
Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
3
2
4
1 |
| 3.2.1.83 | Leukemia |
32654464 |
[Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation]. |
causal interaction
diagnostic usage
ongoing research
unassigned |
1
3
2
0 |
| 3.2.1.83 | Leukemia, Lymphocytic, Chronic, B-Cell |
26212611 |
Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
3
2
4
1 |
| 3.2.1.83 | Lymphoma |
27141398 |
Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells. |
causal interaction
ongoing research
therapeutic application
unassigned |
1
4
1
0 |
| 3.2.1.83 | Lymphoma |
32903866 |
CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain. |
ongoing research
therapeutic application
unassigned |
2
3
0 |
| 3.2.1.83 | Lymphoma |
34010392 |
Development of CAR T-cell lymphoma in two of ten patients effectively treated with piggyBac modified CD19 CAR T-cells. |
diagnostic usage
ongoing research
therapeutic application
unassigned |
1
2
1
0 |
| 3.2.1.83 | Lymphoma |
34312556 |
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. |
diagnostic usage
therapeutic application
unassigned |
3
3
0 |
| 3.2.1.83 | Lymphoma, B-Cell |
34312556 |
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. |
diagnostic usage
therapeutic application
unassigned |
3
3
0 |
| 3.2.1.83 | Lymphoma, Non-Hodgkin |
26212611 |
Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
3
2
4
1 |
